The Alzheimer’s Drug Discovery Foundation has awarded a $900,000 grant to AgeneBio to support the initiation of a Phase 3 clinical trial for AGB101. AGB101 is an investigational therapeutic treatment foramnestic mild cognitive impairment (aMCI).
AGB101 could be the first drug to modify progression of amnestic mild cognitive impairment (aMCI) in patients at a high-risk for progressing to Alzheimer’s dementia
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD January 28, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases, announced today that the Company has…
January 12 – 14, 2015, San Francisco, CA. CEO Jerry McLaughlin spoke on Tuesday, January 13.
BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the Company will present at the 7th Annual Biotech Showcase 2015. Jerry McLaughlin, AgeneBio’s president and…